Nov 20 2017 Posted: 00:00 GMT

Research will help to better understand the mechanisms of immune regulation and can contribute to the development of new treatment strategies for autoimmune diseases such as multiple sclerosis and rejection of transplants

CÚRAM Investigators from NUI Galway’s Regenerative Medicine Institute (REMEDI) and Advanced Glycoscience Research Cluster (AGRC) have been working together to examine how carbohydrate molecules attached to the surfaces of immune cells participate in the normal protective functions of those cells. The groups have published two new studies in the leading open access journal Frontiers of Immunology, which demonstrate that chains of carbohydrate molecules, referred to as glycans, attached to proteins and other components of the cell surface, play an essential role in the function of two very important cells of the immune system.

In the first study, PhD student Joana Cabral with principal investigators Professor Matthew Griffin and Professor Lokesh Joshi, discovered that a specialised type of immune cell, the regulatory T cell (or T-reg), has a distinctive pattern of glycans on its surface compared to other T cell types. T-regs are known to play a policing role in the immune system that prevents inappropriate activation that can lead to autoimmune diseases such as multiple sclerosis and juvenile diabetes or to rejection of transplants. By using enzymes to ‘trim away’ the carbohydrate molecules from the surface of T-regs, Dr Cabral, in collaboration with Dr Jared Gerlach of AGRC, observed that the ability of T-regs to suppress strong immune activity was heavily dependent on their normal glycan pattern. Insights from the research help to better understand the mechanisms of immune regulation and can contribute to the development of new treatment strategies for a range of diseases that involve over- or under-activity of the immune system. Drs Cabral and Gerlach are now part of the CURAM team of researchers

In the second study, PhD student Kevin Lynch, working with CÚRAM Investigator Professor Thomas Ritter and Dr Aideen Ryan from REMEDI, together with Professor Lokesh Joshi investigated how a commonly used steroid medication alters the pattern of carbohydrate molecules on immune cells known as dendritic cells (or DCs). The main function of DCs is to stimulate T-cells to act against foreign molecules (antigens) associated with infectious microbes or, alternatively, to prevent T-cells being activated against harmless antigens, a process known as immune tolerance. Mr Lynch, in collaboration with Dr Jared Gerlach, found that after steroid treatment, DCs develop an increase in specific surface glycans that make them more likely to cause immune tolerance, a finding that may help to design new treatment approaches to prevent or treat autoimmune diseases and rejection of transplants. The group also found that when the same carbohydrate molecules are removed from the surface of DCs, they become more powerful at stimulating active immune responses. This insight may be of particular relevance to cancer treatments which aim to increase T cell activation against antigens contained in tumours.

Commenting on the publication of the studies, Professor Matthew Griffin, Principal Investigator at CÚRAM, said: “The fascinating results we observed by manipulating the surface glycan patterns of T-reg are a beautiful example of the complexity of molecular interactions between different cells of the immune system. The work could not have been successful without a close collaboration between researchers from two very different disciplines. These collaborations have been built, in particular, on NUI Galway’s investment in infrastructure for Biomedical research and on Science Foundation Ireland’s funding support for research clusters in regenerative medicine and glycoscience and, more recently, the CÚRAM centre for research in medical devices.”

Professor Thomas Ritter at NUI Galway, commented: “These results could have important implications for both the field of immunotherapies and cancer treatment. The importance of carbohydrate residues in controlling how immune responses occur is under-studied and warrants further investigations.”

Professor Lokesh Joshi, Co-Lead at CÚRAM and Vice President for Research at NUI Galway, said: “In contrast to the current state of gene and protein biology, many of the details of carbohydrate-based structure and function throughout biology remain mysterious. The results of these studies underscore the importance of understanding complex glycans and their specific cues within the larger mechanisms of cellular interaction. This work provides new avenues for potentially enhancing or regulating elements of immune function. These findings could only have been made possible through collaboration with Professors Ritter and Griffin and the persistence of our respective research teams, all made possible by Ireland’s continuing support of high quality scientific research.”

Professor Michael O’Dwyer, Consultant Haematologist at NUI Galway and Galway University Hospital, and an internationally recognised expert in blood cancers commented: “I am very excited about these results regarding the restoration to immunity after removal of carbohydrate residues on antigen-presenting cells. I am currently working with Professor Ritter and Dr Ryan to investigate the role of glycans in the immune response to blood cancer. The exciting findings of this work, which show that the manipulation of carbohydrate residues on stem cells helps to restore anti-cancer immune response, will be presented later this month at the annual meeting of the American Haematology Society.”

The research studies were supported by individual and centre grants from Science Foundation Ireland as well as a PhD fellowship to Dr Cabral through the Irish Government’s PRTLI5 initiative.


To read the Regulatory T-cells study in Frontiers of Immunology, visit:

To read the dendritic cells study in Frontiers of Immunology, visit:

For more information about the studies contact Professor Matthew Griffin at and Professor Thomas Ritter at


CÚRAM, the Science Foundation Ireland Centre for Research in Medical Devices, is a multidisciplinary centre bringing together research strength and capacity in biomaterials, drug delivery, tissue engineering, regenerative medicine, glycoscience, and device design. The Centre’s vision is to develop affordable, innovative and transformative device-based solutions to treat global chronic diseases. CÚRAM supports industry from basic scientific research, through translational preclinical and clinical development, into regulatory and commercialisation readiness. Find out more at and follow us @curamdevices.

About NUI Galway

The University was established in the heart of Galway City, on the west coast of Ireland, in 1845. Since then it has advanced knowledge teaching and learning, through research and innovation, and community engagement.

Over 18,000 students study at NUI Galway, where 2,600 staff provide the very best in research-led education.

NUI Galway’s teaching and research is recognised through its consistent rise in international rankings. The University is placed in the Top 250 of both the Times Higher Education (THE) World University Rankings 2016/2017 and the QS World University Rankings 2016/17.

With an extensive network of industry, community and academic collaborators around the world, NUI Galway researchers are tackling some of the most pressing issues of our times. Internationally renowned research centres based at NUI Galway include the CÚRAM Centre for Research in Medical Devices, Insight Centre for Data Analytics, Moore Institute, Institute for Life course and Society and The Ryan Institute for Environmental, Marine and Energy.

NUI Galway has been listed as one of the most beautiful universities in Europe according to Business Insider. For more information visit or view all NUI Galway news here.

*The University's official title is National University of Ireland Galway. Please note that the only official abbreviation is NUI Galway.



Latest Press Releases

Contact CÚRAM

+353 (0) 91 495833